Ilaria Brambilla

Dr. Ilaria Brambilla

1. Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, 27100 Pavia, Italy
+1

Research Focus & Metrics

Academic Career Length

61Years (1966-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2018 in Pediatric Allergy, Immunology, and Pulmonology
Verified
Journal Article
Open access
ALAmelia Licari
Amelia Licari
Riccardo CastagnoliRiccardo Castagnoli
Riccardo Castagnoli
Ilaria BrambillaIlaria Brambilla
Ilaria Brambilla
AMAlessia Marseglia
Alessia Marseglia
MTMaria Angela Tosca
Maria Angela Tosca
Giorgio CiprandiGiorgio Ciprandi
Giorgio Ciprandi
Childhood asthma represents a heterogeneous challenging disease, in particular in its severe forms. The identification of different asthma phenotypes has stimulated research in underlying molecular mechanisms, such as the endotypes, and paved the way to the search for related specific biomarkers, which may guide diagnosis, management, and predict response to treatment. A limited number of biomarkers are currently available in clinical practice in the pediatric population, mostly reflecting type 2-high airway inflammation. The identification of biomarkers of childhood asthma is an active area of research that holds a potential great clinical utility and may represent a step forward toward tailored management and therapy: the so-called Precision Medicine. The aim of the present review is to provide an updated overview of asthma endotyping, mostly focusing on novel noninvasive biomarkers in childhood asthma.

18 February 2014 in Clinical Anatomy
Verified
Journal Article
Closed access
PDF file
Ilaria BrambillaIlaria Brambilla
Ilaria Brambilla
APAlessandro Pusateri
Alessandro Pusateri
FPFabio Pagella
Fabio Pagella
DCD. P. Caimmi
D. P. Caimmi
SCSilvia Caimmi
Silvia Caimmi
GMGian Luigi Marseglia
Gian Luigi Marseglia

19 June 2018 in Frontiers in Pediatrics
Verified
Journal Article
Open access
PDF file
ALAmelia Licari
Amelia Licari
Ilaria BrambillaIlaria Brambilla
Ilaria Brambilla
AMAlessia Marseglia
Alessia Marseglia
MFMaria De Filippo
Maria De Filippo
VPValeria Paganelli
Valeria Paganelli
GMGian Luigi Marseglia
Gian Luigi Marseglia
Evaluating the degree of disease control is pivotal when assessing a patient with asthma. Asthma control is defined as the degree to which manifestations of the disease are reduced or removed by therapy. Two domains of asthma control are identified in the guidelines: symptom control and future risk of poor asthma outcomes, including asthma attacks, accelerated decline in lung function, or treatment-related side effects. Over the past decade, the definition and the tools of asthma control have been substantially implemented so that the majority of children with asthma have their disease well controlled with standard therapies. However, a small subset of asthmatic children still requires maximal therapy to achieve or maintain symptom control and experience considerable morbidity. Childhood uncontrolled asthma is a heterogeneous group and represents a clinical and therapeutic challenge requiring a multidisciplinary systematic assessment. The identification of the factors that may contribute to the gain or loss of control in asthma is essential in differentiating children with difficult-to-treat asthma from those with severe asthma that is resistant to traditional therapies. The aim of this review is to focus on current concept of asthma control, describing monitoring tools currently used to assess asthma control in clinical practice and research, and evaluating comorbidities and modifiable and non-modifiable factors associated with uncontrolled asthma in children, with particular reference to severe asthma.

1 August 2018 in Respiratory Medicine
Verified
Journal Article
Closed access
DPDimitri Poddighe
Dimitri Poddighe
Ilaria BrambillaIlaria Brambilla
Ilaria Brambilla
ALAmelia Licari
Amelia Licari
GMGian Luigi Marseglia
Gian Luigi Marseglia

15 September 2017 in Expert Review of Respiratory Medicine
Verified
Journal Article
Closed access
ALAmelia Licari
Amelia Licari
Ilaria BrambillaIlaria Brambilla
Ilaria Brambilla
MFMaria De Filippo
Maria De Filippo
DPDimitri Poddighe
Dimitri Poddighe
Riccardo CastagnoliRiccardo Castagnoli
Riccardo Castagnoli
GMGian Luigi Marseglia
Gian Luigi Marseglia
Introduction: Severe asthma is a complex heterogeneous disease that is refractory to standard treatment and is complicated by multiple co-morbidities and risk factors. Several co-morbidities may contribute to worsen asthma control and complicate diagnostic and therapeutic management of severe asthmatic patients. Areas covered: A prevalent cluster of chronic upper airway co-morbid diseases is recognized in severe asthma. Evaluation for these disorders should always be considered in clinical practice. The aim of this review is to provide an updated overview of the prevalence, the pathogenetic mechanisms, the clinical impact and the therapeutic options for upper airway pathology in severe asthma, focusing on chronic rhinosinusitis and allergic rhinitis. Expert commentary: In the context of severe asthma, the clinical significance of upper airway co-morbidities is based on mutual interactions complicating diagnosis and management. A better analysis and understanding of phenotypes and endotypes of both upper and lower airway diseases are crucial to further develop targeted treatment.

12 July 2019 in Frontiers in Pediatrics
Verified
Journal Article
Open access
ALAmelia Licari
Amelia Licari
SMSara Manti
Sara Manti
Riccardo CastagnoliRiccardo Castagnoli
Riccardo Castagnoli
AMAlessia Marseglia
Alessia Marseglia
TFThomas Foiadelli
Thomas Foiadelli
GMGian Luigi Marseglia
Gian Luigi Marseglia
Childhood asthma is actually defined as a heterogeneous disease, including different clinical variants and partially sharing similar immune mechanisms. Asthma management is mainly focused on maintaining the control of the disease and reducing the risk of adverse outcomes. Most children achieve good control with standard therapies, such as low doses of inhaled corticosteroids (ICS) and/or one or more controller. These medications are targeted to suppress bronchial inflammation and to restore airway responsiveness. However, they are not disease-modifying and do not specifically target inflammatory pathways of asthma; in addition, they are not significantly effective in patients with severe uncontrolled asthma. The aim of this review is to update knowledge on current and novel therapeutic options targeted to immunomodulate inflammatory pathways underlying pediatric asthma, with particular reference on biologic therapies.